The stock value of Enveric Biosciences, Inc. (NASDAQ: ENVB) has significantly increased after the company announced the issue of a ground-breaking patent for its novel chemical series. ENVB’s stock rose 156.78% to $3.03 per share as of the most recent premarket session.
Patent Issuance
A significant milestone for the business was reached on January 14, 2025, when Enveric Biosciences received U.S. Patent No. 12,195,439 from the USPTO. Its recently created EVM401 Series is covered under the patent, “Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives.”
The fact that this landmark patent is the first to be granted for the EVM401 series shows how dedicated Enveric is to developing its line of non-hallucinogenic drugs to treat difficult mental and neurological disorders.
The EVM401 Series’s Potential for Innovation
Enveric’s pipeline will be expanded with the EVM401 Series, which will bring novel non-hallucinogenic compounds that may be crucial in the treatment of addiction and neuropsychiatric conditions. Promising evidence from early research suggests that these mescaline derivative chemicals may have therapeutic uses since they show unique patterns of brain receptor activation.
The substances exhibit interactions with a number of important neurological receptors, such as the dopamine transporter (DAT), the 5-HT2C receptor, and the α2A adrenergic receptor (ADRA2A).
Treatment Consequences for Neuropsychiatric Conditions
New treatment options for drug use disorders, anxiety, depression, ADHD, and opioid withdrawal may be provided by the chemicals of the EVM401 Series. Notably, the 5-HT2C receptor is becoming a crucial target in the treatment of neuropsychiatric disorders, whereas the ADRA2A receptor is well-known for its function in controlling the symptoms of opioid withdrawal.
Strategic Development Pipeline Expansion for Enveric
Enveric Biosciences is concentrating on getting ready for the Investigational New Drug (IND) application for EB-003 in accordance with its strategic direction. The company’s attempts to increase its pipeline and obtain more patents demonstrate its dedication to diversifying its medicinal solutions.
Additionally, to further expand the company’s portfolio, Enveric’s wholly-owned subsidiary Akos Biosciences has signed two licensing agreements with Restoration Biologics LLC with the goal of developing cannabinoid-COX-2 conjugate medicines for the treatment of joint diseases.